Déborah Bauer

3.1k total citations · 2 hit papers
35 papers, 1.9k citations indexed

About

Déborah Bauer is a scholar working on Rheumatology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Déborah Bauer has authored 35 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Rheumatology, 9 papers in Pathology and Forensic Medicine and 6 papers in Molecular Biology. Recurrent topics in Déborah Bauer's work include Multiple Sclerosis Research Studies (5 papers), Urticaria and Related Conditions (5 papers) and Autoimmune and Inflammatory Disorders Research (5 papers). Déborah Bauer is often cited by papers focused on Multiple Sclerosis Research Studies (5 papers), Urticaria and Related Conditions (5 papers) and Autoimmune and Inflammatory Disorders Research (5 papers). Déborah Bauer collaborates with scholars based in United States, France and Canada. Déborah Bauer's co-authors include Robert E. McCullumsmith, James H. Meador‐Woodruff, Herbert Y. Meltzer, W. Rein, Lisa A. Arvanitis, Philippe Truffinet, Myriam Bénamor, Mark Freedman, Vahram Haroutunian and Yong Lin and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and American Journal of Psychiatry.

In The Last Decade

Déborah Bauer

33 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation

2024 102 citations Surya P. Bhatt, Klaus F. Rabe et al. profile →
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

2024 65 citations Marcus Maurer, Thomas B. Casale et al. Journal of Allergy and Clinical Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Déborah Bauer United States	18	564	561	442	391	272	35	1.9k
Philipp von Rosenstiel United States	20	256 0.5×	1.3k 2.4×	307 0.7×	845 2.2×	519 1.9×	55	2.4k
Elena Fumagalli Italy	28	336 0.6×	173 0.3×	324 0.7×	449 1.1×	417 1.5×	104	2.7k
Gilles Edan France	21	318 0.6×	903 1.6×	145 0.3×	177 0.5×	668 2.5×	66	1.8k
H Stępień Poland	28	253 0.4×	175 0.3×	355 0.8×	802 2.1×	217 0.8×	179	2.6k
Jorge E. Ortega Spain	19	325 0.6×	294 0.5×	303 0.7×	323 0.8×	229 0.8×	43	2.0k
Gilmore O’Neill United States	20	245 0.4×	941 1.7×	132 0.3×	453 1.2×	705 2.6×	27	2.0k
Hubert Kwieciński Poland	25	266 0.5×	666 1.2×	821 1.9×	1.4k 3.6×	1.2k 4.3×	102	3.3k
Frédéric Sedel France	25	279 0.5×	375 0.7×	199 0.5×	1.1k 2.9×	461 1.7×	59	3.0k
Anita L. Hawkins United States	31	418 0.7×	307 0.5×	595 1.3×	1.9k 4.9×	264 1.0×	62	4.0k
Luís Brieva Spain	21	303 0.5×	1.0k 1.8×	227 0.5×	295 0.8×	791 2.9×	77	1.8k

Countries citing papers authored by Déborah Bauer

Since Specialization

Citations

This map shows the geographic impact of Déborah Bauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Déborah Bauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Déborah Bauer more than expected).

Fields of papers citing papers by Déborah Bauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Déborah Bauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Déborah Bauer. The network helps show where Déborah Bauer may publish in the future.

Co-authorship network of co-authors of Déborah Bauer

This figure shows the co-authorship network connecting the top 25 collaborators of Déborah Bauer. A scholar is included among the top collaborators of Déborah Bauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Déborah Bauer. Déborah Bauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Funk, Adam J., et al.. (2025). The C. elegans glutamate transporters GLT-4 and GLT-5 regulate protein expression, behavior, and lifespan. Neurochemistry International. 186. 105966–105966. 1 indexed citations

Bhatt, Surya P., Klaus F. Rabe, Nicola A. Hanania, et al.. (2024). Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). Respiratory Medicine. 236. 107846–107846.

Maurer, Marcus, Thomas B. Casale, Sarbjit S. Saini, et al.. (2024). Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. Journal of Allergy and Clinical Immunology. 154(1). 184–194. 65 indexed citations breakdown →

Saini, Sarbjit S., Jonine L. Bernstein, Ana M. Giménez‐Arnau, et al.. (2024). Dupilumab significantly improves itch and hives in patients with chronic spontaneous urticaria (CUPID study C). Annals of Allergy Asthma & Immunology. 133(6). S2–S2. 3 indexed citations

Maurer, Marcus, Thomas B. Casale, Sarbjit S. Saini, et al.. (2024). Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels. Dermatology and Therapy. 14(9). 2427–2441. 9 indexed citations

Bauer, Déborah, et al.. (2023). An Undergraduate Laboratory Series Using C. elegans That Prepares Students for Independent Inquiry. PubMed. 21(2). a133–a141.

Bauer, Déborah, et al.. (2022). A Flame-Free Method for Sterilizing <em>C. elegans</em> Picks, Spatulas, and Scalpels. Journal of Visualized Experiments. 1 indexed citations

Bauer, Déborah, et al.. (2021). Behavioral Differences between Male and Hermaphrodite C. elegans. PubMed. 2021(7). 3 indexed citations

Burmester, Gerd R, Yong Lin, Rahul Patel, et al.. (2016). Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Annals of the Rheumatic Diseases. 76(5). 840–847. 227 indexed citations

10.

Nelson, Flavia, François Evoy, Thomas Berger, et al.. (2015). Efficacy of Teriflunomide in Early-Stage MS: Reanalysis of the TOPIC Study Using 2010 McDonald Diagnostic Criteria (P7.274). Neurology. 84(14_supplement). 2 indexed citations

11.

O’Donovan, Sinead M., Déborah Bauer, Micah Simmons, et al.. (2015). Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia. Translational Psychiatry. 5(6). e579–e579. 51 indexed citations

12.

Miller, Aaron, Philippe Truffinet, Déborah Bauer, & Jerry S. Wolinsky. (2015). Positive MRI Outcomes in Patients with Early Multiple Sclerosis Treated with Teriflunomide: Subgroup Analyses from the TOPIC Phase 3 Study (P7.253). Neurology. 84(14_supplement). 1 indexed citations

13.

Miller, Aaron, Jerry S. Wolinsky, Ludwig Kappos, et al.. (2014). TOPIC: Efficacy and Safety of Once-Daily Oral Teriflunomide in Patients with First Clinical Episode Consistent With Multiple Sclerosis (PL2.002). Neurology. 82(10_supplement). 5 indexed citations

14.

Miller, Aaron, Jerry S. Wolinsky, Ludwig Kappos, et al.. (2014). Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Neurology. 13(10). 977–986. 209 indexed citations

15.

Turner, Benjamin, Déborah Bauer, Myriam Bénamor, Philippe Truffinet, & Aaron Miller. (2014). TERIFLUNOMIDE IN EARLY STAGE MS: RESULTS FROM TOPIC. Journal of Neurology Neurosurgery & Psychiatry. 85(10). e4.58–e4. 1 indexed citations

16.

Vermersch, Patrick, Anna Członkowska, Christian Confavreux, et al.. (2013). Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis Journal. 20(6). 705–716. 244 indexed citations

17.

Bauer, Déborah, et al.. (2012). The glutamate transporter, GLAST, participates in a macromolecular complex that supports glutamate metabolism. Neurochemistry International. 61(4). 566–574. 97 indexed citations

18.

Bauer, Déborah, Vahram Haroutunian, James H. Meador‐Woodruff, & Robert E. McCullumsmith. (2009). Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophrenia Research. 117(1). 92–98. 99 indexed citations

19.

Bauer, Déborah, et al.. (2008). Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia. Schizophrenia Research. 104(1-3). 108–120. 86 indexed citations

20.

Meltzer, Herbert Y., et al.. (2004). Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder. American Journal of Psychiatry. 161(6). 975–984. 249 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact